IQVIA (NYSE:IQV) Sets New 12-Month High – Time to Buy?

IQVIA Holdings Inc. (NYSE:IQV)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $228.22 and last traded at $228.1770, with a volume of 679441 shares trading hands. The stock had previously closed at $224.90.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Citigroup raised their target price on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. Baird R W raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. BMO Capital Markets assumed coverage on shares of IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective for the company. JPMorgan Chase & Co. raised their price target on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Finally, HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $240.61.

IQVIA Stock Performance

The company has a 50-day simple moving average of $206.64 and a two-hundred day simple moving average of $181.78. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market cap of $38.86 billion, a PE ratio of 31.30, a PEG ratio of 2.52 and a beta of 1.34.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the prior year, the firm earned $2.84 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently modified their holdings of the company. Physician Wealth Advisors Inc. lifted its holdings in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares during the last quarter. Westside Investment Management Inc. raised its position in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in IQVIA in the third quarter worth $30,000. Clal Insurance Enterprises Holdings Ltd boosted its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the period. Finally, Atlantic Union Bankshares Corp bought a new position in shares of IQVIA during the third quarter valued at about $36,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.